Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

722
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
722
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Drug Therapy01:28

Drug Therapy

224
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
224
Dementia01:30

Dementia

470
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
470
Modeling in Therapy01:26

Modeling in Therapy

344
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
344
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

485
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
485

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-Type-Selective Cortical Pathology and Functional Deficits in Synucleinopathy.

bioRxiv : the preprint server for biology·2026
Same author

Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody Functions.

bioRxiv : the preprint server for biology·2026
Same author

Autophagosome-targeting single-domain antibody clears tau in patient-derived neurons and improves motor function in tauopathy mice.

Science translational medicine·2026
Same author

Corrigendum to "Formaldehyde induces and promotes Alzheimer's disease pathologies in a 3D human neural cell culture model" [Food Chem. Toxicol. (2025 Dec) 206 115777].

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025
Same author

Formaldehyde induces and promotes Alzheimer's disease pathologies in a 3D human neural cell culture model.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025
Same author

Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice.

Cell reports·2025

Related Experiment Video

Updated: Jan 4, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Alzheimer's therapy development: A few points to consider.

Einar M Sigurdsson1

  • 1Departments of Neuroscience and Physiology, and Psychiatry, Neuroscience Institute, New York University School of Medicine, New York, NY, United States.

Progress in Molecular Biology and Translational Science
|November 9, 2019
PubMed
Summary

Developing effective Alzheimer's disease (AD) therapies requires targeting tau protein intracellularly and inhibiting aggregate neurotoxicity, not just preventing spread. Future drug development should consider tau strains and explore broader neurodegeneration targets alongside amyloid-beta and tau.

Keywords:
Alzheimer's diseaseAmyloid-βAntibodiesDrug developmentDrug screeningImmunotherapyNeurotoxicitySeedingStrainsTauTherapy

More Related Videos

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.6K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K

Related Experiment Videos

Last Updated: Jan 4, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.6K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Current Alzheimer's disease (AD) therapies offer limited symptomatic relief and do not halt disease progression.
  • Numerous clinical trials targeting amyloid-beta and tau proteins have failed to demonstrate efficacy.
  • Existing treatment strategies have not addressed the intracellular nature of tau pathology or the neurotoxicity of protein aggregates.

Purpose of the Study:

  • To identify key challenges and propose improvements for future Alzheimer's disease (AD) drug development.
  • To highlight the importance of intracellular tau targeting and inhibiting aggregate neurotoxicity.
  • To discuss the impact of tau aggregate conformers and suggest alternative therapeutic strategies.

Main Methods:

  • Review of current Alzheimer's disease (AD) therapeutic approaches and clinical trial outcomes.
  • Analysis of the limitations in targeting tau protein and amyloid-beta aggregates.
  • Consideration of drug screening models focusing on neurotoxicity versus aggregate spread.

Main Results:

  • Intracellular targeting of tau pathology is crucial, as most tau pathology resides within neurons.
  • Inhibiting the neurotoxicity of tau and amyloid-beta aggregates is as important as preventing their spread.
  • Drug development must account for diverse tau aggregate conformers, potentially favoring antibody-based treatments.

Conclusions:

  • Future AD therapies should prioritize intracellular tau targeting and inhibition of aggregate neurotoxicity.
  • Drug screening assays should incorporate readouts for both aggregate spread and neurotoxicity.
  • While amyloid-beta and tau remain key targets, pursuing broader neurodegeneration pathways may also be necessary.